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Neuroblastoma (NB) is the most common and aggressive pediatric cancer, characterized by a remarkable phenotypic diversity
and high malignancy. The heterogeneous clinical behavior, ranging from spontaneous remission to fatal metastatic disease, is
attributable to NB biology and genetics. Despite major advances in therapies, NB is still associated with a high morbidity and
mortality. Thus, novel diagnostic, prognostic, and therapeutic approaches are required, mainly to improve treatment outcomes
of high-risk NB patients. Among neuroepithelial cancers, NB is the most studied tumor as far as PPAR ligands are concerned.
PPAR ligands are endowed with antitumoral effects, mainly acting on cancer stem cells, and constitute a possible add-on therapy to
antiblastic drugs, in particular for NB with unfavourable prognosis. While discussing clinical background, this review will provide
a synopsis of the major studies about PPAR expression in NB, focusing on the potential beneficial effects of hypoglycemic drugs,
thiazolidinediones and metformin, to reduce the occurrence of relapses as well as tumor regrowth in NB patients.
1. Introduction
(1) Neuroblastoma. Neuroblastoma (NB) is a tumor of the
developing sympathetic nervous system observed in early
childhood, which is characterized by a broad spectrum of
clinical behaviors, ranging fromcomplete regression to death.
NB represents the second most common extracranial
malignancy of childhood, accounting for 8 to 10% of all
childhood cancers (NB prevalence is about one case in 7,000–
10,000 live births) and for approximately 15% of the pediatric
deaths for malignant conditions [1].
The clinical presentation of NB ranges from asymp-
tomatic masses to primary tumors that cause critical illness
due to local invasion and/or widely disseminated disease.
Most primary NB (65%) usually present in the abdominal
region, often in the adrenal medulla. Other common sites of
disease include the neck and head (5%), chest (20%), and
pelvis (5%) [1].
NB is a disease of the sympaticoadrenal lineage of the
neural crest and originates from neuroblasts in the develop-
ing peripheral nervous system [2].
In recent years, it has been suggested that NB tumori-
genesis is dependent on the presence of cancer stem cells
(CSCs), which have been also isolated from NB cell lines
[3, 4]. CSCs are thought to be also responsible for metastasis
and recurrence in NB patients [5, 6].
Cellular heterogeneity is a hallmark of NB nodules and
the prognosis of these tumors depends on their differentia-
tion levels [7]. Interestingly, cell lines established from several
human NB retain similar cellular heterogeneity.
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Biedler et al. described three cell subtypes, often dis-
cernible also in NB cell line cultures, based on cell morphol-
ogy, biochemical features, and growth patterns [8]: (i) N-type
(neuroblastic: aggregated, poorly attached, and rounded cells
with short neurites); (ii) S-type (substrate-adherent and non-
neuronal cells); and (iii) I-type (intermediate: mildly adher-
ent cells, showing marked stem-like traits, representing can-
cer stem-like cells population, and being thought to originate
both S- and N-type cells) [7].
Several studies have shown that these cell types derive
from a common precursor and are able to bidirectionally
differentiate. This bidirectional conversion between well-
defined differentiation lineages of the neural crest has been
termed “transdifferentiation” [9].
Because the transdifferentiation process is able to also
allow the differentiating of malignant CSCs into benign
phenotype, a novel concept in cancer biology was intro-
duced: “induction of differentiation” as possible treatment
(e.g., using retinoids to treat NB and acute promyelocytic
leukaemia [10]).
The cause of NB development is still unclear occurring
mostly as sporadic disease but also rare (about 1% of all cases)
familial cases were reported [1]. Genomic alterations are
associatedwithNBdevelopment and/or progression,many of
which have proven to be correlatedwith clinical outcome.The
most widely studied cytogenetic alterations, associated with
poor outcome in NB, include N-myc oncogene amplification,
loss or rearrangement of the distal portion of the short arm
of chromosomes 1 (1p31-term), 3 (3p22), and 11 (11q23), gains
of chromosome arm 1q or 17q, and the expression of the
TrkB neurotrophin receptor and its ligand [34–38]. Other
cytogenetic and molecular abnormalities are likely involved
in NB pathogenesis and their identification could be useful
for diagnosis, prognosis, and therapy of NB patients.
Traditional NB treatments include surgery, chemother-
apy, radiotherapy, and biotherapy [34]. However, themajority
of NB patients (50%) have poor outcomes and relapses,
remaining a clinical challenge.
Unfortunately, in many cases, by the time of diagnosis,
the disease has usually spread already. In these cases, the
mainstay treatment is frequently intensive regimens includ-
ing combinations of high doses of chemotherapeutics [39]
that often are accompanied by unacceptable high toxicities
and no long-term improvements. Innovative approaches are
therefore needed for this disease. The new treatment proto-
cols for NB currently under investigation consist of targeted
radiotherapy and retinoid compounds (to induce terminal
differentiation of NB cells), immunological treatment, such
as using antidisialoganglioside 2 with or without associa-
tion with cytokines (GM-CSF, IL-2), antiangiogenics, neuro-
trophin-signaling inhibitors, proapoptotic agents, allogeneic
haemopoietic stem cell transplantation, and new chemother-
apeutics [34, 39].
(2) PPARs. Peroxisome proliferator-activated receptors
(PPARs) are ligand-activated transcription factors belonging
to the nuclear receptor superfamily.
PPARs are activated by fatty acids, eicosanoids, other
dietary lipids, and theirmetabolites, or synthetic ligands [40],
which have been pharmacologically used in several diseases,
making PPARs attractive therapeutic targets.
There are three PPAR isoforms (𝛼, 𝛽/𝛿, and 𝛾) which
are encoded by separate genes [41] and are expressed during
different stages of prenatal development [42].
Through the regulation of the expression of multiple
genes [43], PPARs control several physiological processes,
including cell proliferation, morphogenesis, differentiation,
and cellular homeostasis [44, 45], and have been implicated
in different human diseases such as hyperlipedimia, diabetes,
obesity, inflammation, neurodegenerative disorder, cardio-
vascular diseases, and cancer [46–49].
Although all PPAR isoforms display a partially overlap-
ping spectrum of activity, essentially as far as the control of
lipid and energymetabolism is concerned, they differ in tissue
expression pattern and functional roles [50–52].
PPAR-𝛼 is predominantly expressed in metabolically
active tissues, such as liver, skeletal muscle, heart, intestinal
mucosa, brown adipose tissue, adrenal gland, pancreas, and
kidney. This receptor regulates catabolism of fatty acids and
promotes lipolysis and fatty acid oxidation [53–56].
PPAR-𝛼 endogenous ligands (fatty acids and several fatty-
acid-derived compounds) or synthetic pharmacological ago-
nists (fibrate drugs, WY14643 and GW7647) have been iden-
tified [57], and some of them are currently used for the treat-
ment of hypertriglyceridemia and cardiovascular diseases
[58].
PPAR-𝛽/𝛿 is ubiquitously expressed particularly in liver,
intestine, kidney, abdominal adipose tissue, skeletal muscle,
andmacrophages. It regulates energy expenditure, participat-
ing in fatty acid oxidation and regulating blood cholesterol
concentrations and glucose levels [41, 54, 59].
PPAR-𝛽/𝛿 agonists are prostacyclin PGI2, oleic acid, and
synthetic agents, such as GW501516, GW7842, and GW0742,
which attenuate hepatic steatosis [60].
PPAR-𝛾 is expressed within adipose tissue, the large
intestine, spleen, skeletal muscle, liver, pancreas, endothelial
cells, immune cells, various cancer cells, and brain [61–63].
It regulates energy storage and has a key role in fatty
acid metabolism and glucose homeostasis [55, 64–66],
mitochondrial biogenesis, and ROS metabolism [67, 68].
Many lipids, including eicosanoids and the cyclopentenone
prostaglandin 15-deoxy-Δ12,14-prostaglandin J2 (15-deoxy-
PGJ2), are endogenous PPAR-𝛾 ligands, while synthetic ago-
nists include thiazolidinediones (TZDs), GI262570, GW1929,
and GW7845 [69]. PPAR-𝛾 has been extensively studied as a
pharmacological target in several diseases.
TZDs are the best-characterized pharmacological PPAR-
𝛾 agonists, and, among them, pioglitazone and rosiglitazone
have been approved by FDA for treatment of type II diabetes
[70–72].
In addition, another oral hypoglycemic drug, metformin,
which directly improves insulin action, modulating AMPK
activity (a key energy regulator), increases PPAR-𝛾 mRNA
levels [73], acting similarly to rosiglitazone [74].
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Interestingly, it has been suggested to use PPARs as target for
cancer treatment, and several PPAR agonists, in particular
acting on PPAR-𝛾, represent promising therapeutic tools as
antitumoral agents [75]; PPAR-𝛾 agonists were reported to
inhibit cell growth and to induce apoptosis in several cancer
cell lines in vitro and in vivo [76–86], including NB cells
[87, 88].
All three PPARs isoforms have been identified in NB,
although human NB cell lines express PPAR-𝛼 (mRNA or
proteins) at very low level [11, 89–91], and PPAR-𝛽/𝛿 expres-
sion data are still incomplete [11, 92]. Conversely, PPAR-𝛾 is
highly expressed in NB cell lines [11, 12] and in primary NB
cell cultures [75], being mainly localized in the nuclei rather
than in the cytoplasm and being particularly expressed in
cells showing ganglionic differentiation [11, 89].
In addition, it has been documented that embryonic rat
brain and neural stem cells have higher concentration of
PPAR-𝛾 than adult rat brain [42, 93]. In neural stem cells,
PPAR-𝛾 is involved in the regulation of proliferation and
differentiation [94].
Interestingly, PPAR-𝛾 expression is correlated to the mat-
urational stage of NB and therefore to NB patients’ outcome
[85], and PPAR-𝛾 agonists induce NB cell differentiation,
inhibiting proliferation, neurite outgrowth, and reducing N-
myc levels [11].
2.1. PPARs Agonists in Neuroblastoma. Several studies have
assessed the activity of PPAR-𝛾 inNB, evaluating the effects of
several natural or synthetic ligands on cellular proliferation,
apoptosis, and differentiation (Table 1).
15-deoxy-Δ12,14-prostaglandin J2 (15-deoxy-PGJ2), a
high-affinity natural ligand of PPAR-𝛾, inhibits in vitro
growth and induces apoptosis in NB cells [11–16], through
PPAR-𝛾-dependent ERK2 activation, althoughPPAR-𝛾-inde-
pendent effects of 15-deoxy-PGJ2 have been also described
[14].
In addition, Rodway et al. have found that the inhibition
of NB growth induced by 15-deoxy-PGJ2 can be reduced
by the presence of serum lysolipids in the culture medium
[14], while Emmans et al. reported that the degree of PPAR
activation, due to 15-deoxy-PGJ2, in a NB cell line, is atten-
uated in the presence of the retinoblastoma protein (Rb) and
restored by treatment with the histone deacetylase inhibitor
trichostatin A (TSA). The combination treatment with 15-
deoxy-PGJ2 and TSA enhances the inhibition of NB growth,
suggesting a synergistic activity of the two compounds [13].
Furthermore, 15-deoxy-PGJ2 promotes NB cell differenti-
ation, which may be mediated by the p38 MAP kinase
activation and the AP-1 signaling pathway [95].
Synthetic PPAR-𝛾 ligands have been also tested to con-
trast NB cell growth.
Han and coworkers firstly evaluated the effect of the
synthetic ligand, GW1929, in the NB cell line LA-N-5, and
found that this compound induces cell differentiation and
inhibits proliferation [11].
GW1929 prodifferentiating effect was shown to be depen-
dent on PPAR-𝛾 activation, as demonstrated by the use of
specific antagonists [96].
In 2005, Valentiner et al. tested the effects of four TZDs
(ciglitazone, pioglitazone, troglitazone, and rosiglitazone) in
seven NB cell lines (i.e., Kelly, LAN-1, LAN-5, LS, IMR-32,
SK-N-SH, and SH-SY5Y) [17]. All the ligands, in particular
ciglitazone and rosiglitazone, inhibited cell proliferation and
viability in a dose-dependent manner, with different drug
effectiveness among cell lines. Moreover, drug potency was
not related to PPAR-𝛾 protein amount in NB cell lines,
but rather to various cellular conditions associated with the
receptor function.
The antiproliferative effect of rosiglitazonewas confirmed
by the same group in vivo, in a metastatic xenograft mouse
model [18], although its antitumor effect was very limited.
Ciglitazone was also used in association with 15-deoxy-
PGJ2 to overexpress Rb protein and inhibit PPAR-𝛾 activity,
reducing NB cell growth [13].
Servidei et al. tested 15-deoxy-PGJ2 and rosiglitazone on
8 NB cell lines, with different phenotypes, including N- and
S-types [12]. The two PPAR-𝛾 ligands inhibit cell growth in
all cell lines, and the sensitivity seems to be more associated
with the cell phenotype thanwith PPAR-𝛾 expression: indeed,
N-type cells are more susceptible to treatment than S-type
cells, partly because of their higher capability of undergoing
apoptosis.
Many studies have documented that the inhibitory effects
of TZDs on neuroblastoma cell growth are partially due to
an increase of apoptosis. Indeed, troglitazone induced PPAR-
𝛾-dependent apoptosis in NB-1 cells [19] and in SHEP NB
[20]. In contrast, only two studies, to our knowledge, reported
antiapoptotic effects of rosiglitazonewhich protectedNB cells
subjected to MPP+-induced mitochondrial injury reducing
ROS production [21, 22].
Proapoptotic effects of rosiglitazone were also reported
[23]. This PPAR-𝛾 ligand significantly inhibits cell adhesion
and invasiveness and induces apoptosis, more effectively in
SK-N-AS than in SH-SY5Y cell lines. The distinct response
of the two NB cell lines is likely due to a reduced phospho-
rylation of PPAR-𝛾 and consequently its increased activity
in SK-N-AS cells. Cellai and colleagues also evaluated the
in vivo effect of TZDs in NB xenograft models, confirming
their previous in vitro observations [24]. Indeed rosiglitazone
(150mg/kg/day) for 4 weeks significantly reduced tumor
growth (−70%) as compared to control mice [24].
In addition, rosiglitazone induces differentiation, increas-
ing density of dendritic spines in rat primary cortical neurons
[25].
Moreover, in neural stem cells (NSC) from adult mam-
malian brain, pioglitazone and rosiglitazone directly regulate
proliferation, differentiation, and migration [26].
Accordingly, Miglio et al. described the effects of piogli-
tazone on SH-SY5Y NB cells, in which this agonist promotes
differentiation and outgrowth of cell processes, in a dose-
dependent manner [27]. In 2014, Chiang et al. evaluated
the effects of rosiglitazone in the mouse NB Neuro 2a
(N2A) cell line.This agonist stimulates neurite outgrowth and
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Table 1: Preclinical and experimental studies on PPAR agonists in neuroblastoma.





PPAR-𝛾 In vitro NB cell lines and primarycultures of cortical neurons












Inhibition of cell growth with
different sensitivity related to the
cell phenotype.
Ciglitazone and
15-deoxy-PGJ2 [13] 2004 PPAR-𝛾 In vitro
SK-N-AS, IMR-32, SK-N-SH,
and ND-7
Overexpression of Rb protein
and inhibition of PPAR-𝛾






[17] 2005 PPAR-𝛾 In vitro Kelly, LA-N-1, LA-N-5, LS,IMR-32, SK-N-SH, and SH-SY5Y
Inhibition of cell proliferation
and viability in a dose-dependent
manner.
Rosiglitazone [18] 2010 PPAR-𝛾 In vivo SK-N-SH xenograft NB mousemodel Inhibition of tumor growth.
Troglitazone [19] 2002 PPAR-𝛾 In vitro NB-1 cell line Increase of PPAR-𝛾-dependentapoptosis.
Troglitazone [20] 2006 PPAR-𝛾 In vitro SHEP NB cell line Increase of PPAR-𝛾-dependentapoptosis.
Rosiglitazone [21, 22] 2006,2007 PPAR-𝛾 In vitro SH-SY5Y cell line
Antiapoptotic effects of
rosiglitazone which protected NB
cells subjected to MPP+-induced
mitochondrial injury reducing
ROS production.
Rosiglitazone [23] 2006 PPAR-𝛾 In vitro SK-N-AS and SH-SY5Y cell lines
Inhibition of cell adhesion,
invasiveness, and proapoptotic
effects.
Rosiglitazone [24] 2010 PPAR-𝛾 In vivo SK-N-AS xenograft NB mousemodel
Significant decrease of tumor
growth (−70%) as compared to
control mice.
Rosiglitazone [25] 2008 PPAR-𝛾 In vitro Rat primary cortical neurons








Adult male Wistar rats
Induction of proliferation,
differentiation, and migration of
neural stem cells in vitro and in
vivo.
Pioglitazone [27] 2009 PPAR-𝛾 In vitro SH-SY5Y cell line
Induction of differentiation and
neurite outgrowth, promoting
differentiation and outgrowth of
cell processes.
Rosiglitazone [28] 2014 PPAR-𝛾 In vitro Mouse NB Neuro 2a (N2A) cellline
Stimulation of neurite outgrowth
and significant increase of the
population of neurite-bearing
cells, via PPAR-𝛾 pathway.
Oleic acid or
GW0742 [29] 2007 PPAR-𝛽/𝛿 In vitro SH-NH-5YSY cell line
Induction of G1 cell cycle arrest,
reduction of cell migration and
invasiveness, and an increase of
neuronal differentiation.
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significantly increases the population of neurite-bearing cells,
via PPAR-𝛾 pathway [28].
All these observations are in agreement with previous
findings indicating that PPAR-𝛾 activation contributes to
neuronal differentiation [11, 94–99].
While PPAR-𝛾 activation mainly results in apoptosis
promotion in proliferating cells, PPAR-𝛽/𝛿 natural (i.e., oleic
acid) and synthetic (i.e., GW0742) agonists induce G1 cell
cycle arrest, reduce cell migration and invasiveness, and
increase neuronal differentiation in SH-NH-5YSY [29].
In summary, all these results suggest the possible use of
PPAR agonists as novel therapy forNB, but to date clinical tri-
als are not yet underway (http://www.who.int/topics/clinical
trials/en/).
2.2. Metformin and Neuroblastoma. Beyond TZDs, met-
formin is another hypoglycemic drug able to modulate PPAR
expression or activity, although these effects are rather cell
specific and mainly indirectly mediated by the activation of
AMPK.
Metformin is biguanide with a well-known safety profile,
mainly used as oral antidiabetic drug [100, 101], whose
promising anticancer activity was recently discovered [102].
It is well-documented that metformin inhibits tumor growth
in in vitro and in vivo preclinical cancermodels [103–110], and
various human clinical trials are in progress (WHO Interna-
tional Clinical Trials Registry Platform, http://www.who.int/
topics/clinical trials/en/).
In particular, metformin seems to selectively affect cancer
stem cell survival, inhibiting cancer metastases and thus
represents a good potential adjuvant agent for chemotherapy
(as reviewed by [111]).
However, the molecular mechanisms of action of met-
formin are still not completely defined, although it seems that
the antiproliferative mechanisms induced by this drug are at
least partially diverging from those regulating glucose home-
ostasis. While the latter is mainly dependent on the AMPK
activation, the antitumor activity ofmetformin ismediated by
inhibition of AKT/mTOR (also involving AMPK), the inhi-
bition of TK activity, or the regulation of chloride channels
[112–116].
As far as the effects of metformin on PPAR activity are
concerned, several studies were performed but the results
are extremely dependent on the receptor subtype and the
cells analyzed. For example, metformin increased PPAR-𝛽/𝛿
expression in muscle cells and activity in endothelial cells
[117, 118], reducing the effects of ER stress and increasing
the bioavailability of nitric oxide [119]. On the other hand,
metformin counteracts antiosteogenic PPAR-𝛾 activation by
rosiglitazone in bone marrow progenitor cells [120] and both
PPAR-𝛾 and PPAR-𝛼 activity in hepatoma cells [121]. Finally,
a PPAR-𝛼 activation role of metformin was identified to
increase GLP-1 receptor levels [122].
However, although demonstrated in several models, the
role of the modulation of PPAR expression and/or activity in
the antiproliferative effects of metformin in neuroblastoma
has not been addressed yet.
The effect of metformin on NB was firstly demonstrated
by our groups [30].
We reported that the effects of metformin treatment in
human SKNBE2 and SH-SY5Y NB cell lines are a significant
reduction in the proliferation rate and cell viability, due to
inhibition of AKT phosphorylation and an increased cell
death, via apoptosis-independent pathways. These effects
were more pronounced in SKNBE2, which are less differen-
tiated, highly proliferative cells than SH-SY5Y cells. Notably,
metformin effects were different depending on the differen-
tiating stimuli, being abolished by retinoic acid, but were
potentiated by overexpression of NDM29, a noncoding RNA
affecting NB malignancy, although both conditions were
characterized by a neuron-like differentiated phenotype [30,
123–128].
These in vitro results are in agreement with those of
Kumar and coworkers who evaluated the antitumor activ-
ity of metformin against neuroblastoma in vivo [31]. Oral
administration of metformin, in both SH-SY5Y and SK-
N-BE xenograft NB mouse models, significantly inhibited
the growth of the tumors. NB cell viability is reduced by
metformin, which also interferes with spheroid formation in
3D cultures, confirming that its antitumor effect could also
involve the inhibition of CSC self-renewal. Moreover, in this
study, it was confirmed that SKNBE2 cells are more suscep-
tible to metformin than SH-SY5Y cells. In addition, studying
the underlying signaling mechanisms, they highlighted that
a modulation of Rho-GTPases and MAP kinase activation
mediate metformin effects on NB cell survival.
In the same year, Vujic et al. successfully used metformin
to inhibit cell proliferation and induce apoptosis in NRAS
mutant NB cell lines (SK-N-AS and CHP-212), in which
NRAS signaling is constitutively active through the PI3K/
AKT/mTOR pathway [32].
In 2015, Mouhieddine and colleagues found that met-
formin reduces proliferation rate, viability, and invasive
potential of NB cell lines SH-SY5Y [33].
Interestingly, focusing on metformin effect on stem cell
populationwithin a 3D culturemodel, these authors reported
that this drug is able to decrease, but not abolish, cell sphere-
forming ability, significantly targeting and reducing cancer
stem/progenitor cell population and thus possibly preventing
recurrence.
Notably, metformin also reduces MMP-2, a protein
involved in extracellular matrix degradation, favoring metas-
tasis and cancer progression [33].
Thanks to the highly selective and cytotoxic effects of
metformin on NB cells and on stem cell population in
particular (Table 2), these studies suggest that high-risk NB
patients could have great benefit by using metformin in
terms of increasing disease prognosis and propose that this
drug can also be used as a novel therapeutic agent against
neuroblastoma.However, at themoment, there are no clinical
trials evaluating metformin efficacy for the treatment of NB
(WHO International Clinical Trials Registry Platform, http://
www.who.int/topics/clinical trials/en/).
3. Conclusion
Despite advances in standard therapeutic protocols, the prog-
nosis of NB has not gained significant progress, especially
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Table 2: Studies on metformin treatment to date in neuroblastoma.
Reference/s Year Study types Cell lines/animal model Effects
[30] 2014 In vitro SKNBE2 and SH-SY5Y celllines
Significant reduction in the proliferation rate and cell
viability, due to inhibition of AKT phosphorylation,
and an increased cell death, via apoptosis-independent
pathways.




Significant inhibition of tumor growth and NB cell
viability, interfering with spheroid formation in 3D
cultures. Modulation of Rho-GTPases and AMPK
activation mediate metformin effects on NB cell
survival.
[32] 2015 In vitro SK-N-AS and CHP-212 celllines
Inhibition of cell proliferation and induction of
apoptosis.
[33] 2015 In vitro SH-SY5Y cell line Reduction of proliferation rate, viability, and invasivepotential.
concerning the rates of metastasis, the incidence of recur-
rences, and the long-term survival, which are all correlated
with the presence of CSCs.
Recently, many groups focused their attention on PPARs,
suggesting the use of several PPAR agonists, currently used as
hypoglycemic drugs, for NB treatment. Interestingly, many
in vitro and in vivo studies reported the successful use of
PPAR agonists, and in particular of TZDs, in the inhibition of
NB cell proliferation and tumor growth, in the induction of
cell death, and in the promotion of cell differentiation. These
effects are PPAR-dependent, even if some PPAR-independent
effects have been also described. Notably, PPAR agonists also
reduce the viability of CSCs, the tumor cell subpopulation
responsible of NB recurrence. Similar results were obtained
with another hypoglycemic drug, metformin, which acts also
via the modulation PPAR activity. In the future, it will be
important to examine the contribution of PPARs in the
antiproliferative activity of metformin and the possible syn-
ergistic effect with known or novel selective PPAR agonists.
Although further studies in vitro as well as in vivo are
needed, these hypoglycemic drugs may represent realistic
new therapeutic approaches to be used as good adjuvant
chemotherapeutic agents in NB treatment.
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